Navigation Links
Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
Date:2/3/2012

LOVELAND, Colo., Feb. 3, 2012 /PRNewswire/ -- Heska Corporation (Nasdaq: HSKA) announces the following Webcast: What:

Heska Corporation Invites You to Join Its Fourth Quarter and Year-End 2011 Earnings Conference Call on the Web 

 When:

Friday, February 17, 2012 @ 9:00 a.m. (MST) 

 Where:

www.heska.com (click on the Q4 and Year-End 2011 Earnings Call link on the front page of this website) 

 How:

Live over the Internet -- Simply log on to the web at the address above.  Alternatively, you may use the following teleconference access numbers:  Domestic: 877-941-0844; International: 480-629-9835; Conference Call Access Number: 4511908.

If you are unable to participate during the live webcast, the call will be archived at www.heska.com until March 2, 2012.  To access the replay, click on the Q4 and Year-End 2011 Earnings Call link on the front page of this website.  Alternatively, you may use the telephone replay through March 2, 2012 at the following:  Domestic: 800-406-7325; International: 303-590-3030; Conference Call Access Number: 4511908.

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at

SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd
2. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
3. Palomar Medical Technologies to Host Fourth Quarter and Year End 2011 Financial Results Conference Call and Webcast on February 9, 2012 at 11:30 AM Eastern Time
4. Thoratec Schedules Fourth Quarter Conference Call, Webcast
5. BD Announces Webcast of Annual Meeting of Shareholders
6. ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results
7. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
8. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
9. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2011 Financial Results Conference Call
10. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2012 Results
11. Hill-Rom Holdings, Inc. Hosts Fiscal 2012 First Quarter Earnings Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)...  Avaxia Biologics, Inc., a privately-held biotechnology ... locally within the gastrointestinal tract, announced today ... 8,182,818, entitled "Methods of Using Anti-TNF Antibodies ... Tract." This patent provides broad ... to treat radiation induced damage to the ...
(Date:5/22/2012)...  Upsher-Smith Laboratories, Inc. announced today that Senior ... McKesson Branded Pharmaceutical Representative of the Year Award ... Las Vegas, NV on May 8, 2012.  The ... President of Purchasing at McKesson.  ... CA-based McKesson, one of the largest pharmaceutical distributors ...
(Date:5/22/2012)... -- APEX BIOSTRATEGISTS, A FULL SERVICE ADVISORY FIRM, LED ... SALE BY NPE SYSTEMS, INC. AND BLUE OCEAN BIOMEDICAL, ... NPE AND BLUE OCEAN WERE TECHNOLOGY LEADERS IN THE ... TISSUE TESTING FOR PATIENT MONITORING AND FOR DRUG RESEARCH. ... OF FLOW CYTOMETRY SYSTEMS TO HOSPITALS AND TESTING LABS ...
Breaking Medicine Technology:Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation 2Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation 2Apex BioStrategists Advises On Flow Cytometry Sale To Coulter 2Cedars Sinai awarded 241 9 million from CIRM to develop stem cell treatments for osteoporosis 76539 1Cedars Sinai awarded 241 9 million from CIRM to develop stem cell treatments for osteoporosis 76539 2Medivir Interim Report 1 January 30 September 2010 12006 1Medivir Interim Report 1 January 30 September 2010 12006 2Medivir Interim Report 1 January 30 September 2010 12006 3Medivir Interim Report 1 January 30 September 2010 12006 4Medivir Interim Report 1 January 30 September 2010 12006 5Medivir Interim Report 1 January 30 September 2010 12006 6Medivir Interim Report 1 January 30 September 2010 12006 7Medivir Interim Report 1 January 30 September 2010 12006 8Essilor Third Quarter 2010 Report 12004 1Essilor Third Quarter 2010 Report 12004 2Essilor Third Quarter 2010 Report 12004 3Essilor Third Quarter 2010 Report 12004 4Essilor Third Quarter 2010 Report 12004 5Essilor Third Quarter 2010 Report 12004 6Essilor Third Quarter 2010 Report 12004 7Essilor Third Quarter 2010 Report 12004 8Essilor Third Quarter 2010 Report 12004 9Essilor Third Quarter 2010 Report 12004 10
... Nektar,Therapeutics (Nasdaq: NKTR ) today ... study,for NKTR-118 (PEG-naloxol), an oral treatment being ... clinical manifestations of,opioid-induced bowel dysfunction (OBD). The ... safety and tolerability,of NKTR-118 in patients experiencing ...
... Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy and ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and commercializing,products ... of the INFUSE-LR clinical trial results in the Journal,of Palliative ...
Other Medicine Technology:Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 2Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 3Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 4Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 5Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/22/2012)... Large randomized controlled trials (RCTs) are critical for ... Yet Canada provides scant support for these studies ... in CMAJ ( Canadian Medical Association ... and Hamilton Health Sciences, Hamilton, Ontario, with Dr. ... the analysis and appendix that Canada should provide ...
(Date:5/22/2012)... The University of Kentucky Markey Cancer Center has ... blood and bone marrow disease often caused by chemotherapy ... Edward P. Evans Foundation, along with a $1.25 million ... , The Evans Foundation grant will fund five research ... one at Cincinnati Children,s Hospital, and one at the ...
(Date:5/22/2012)... 2012) -- Researchers at Barrow Neurological Institute at ... how and why the public perceives some magic ... implications in military tactics, marketing and sports. , ... Neuroscience, and Stephen Macknik, PhD, of Barrow,s Laboratory ... research into magic and illusions. Their most recent ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
(Date:5/22/2012)... (May 22, 2012) -- Up to half of all prostate ... new "fusion" gene and formation of its unique protein -- ... growth. Now, Weill Cornell Medical College researchers have found that ... up in a little ball known as a chromatin, is ... thrown on thousands of genes, turning them on or off ...
Breaking Medicine News(10 mins):Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3Health News:Barrow researchers use magic for discoveries 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4Health News:Scientists unravel role of fusion gene in prostate cancer 2Health News:Scientists unravel role of fusion gene in prostate cancer 3Health News:Scientists unravel role of fusion gene in prostate cancer 4
... or incapable of quitting smoking, but are prepared to try ... . ,However, after studying healthcare literature, a team ... been given to this alternative of cutting down the number ... at smokers has been at helping them to stop smoking ...
... cheap. But the new bionic hand, developed by a Scottish engineer, is ... ,It can't click its fingers or play the piano but there's ... instance, turn a key in a lock, hold a wine glass ... ,David Gow who works with with Lothian NHS in Scotland and the ...
... that combining a non-pyrethroid insecticide, propoxur, and a ... effective insecticide-repellent synergy against mosquitoes responsible for ... of the two had proved to be much ... respective properties. Mosquito nets soaked with this mixture ...
... Mwanawasa on Thursday opened a 10 million dollar specialist cancer ... for the first time . ,Mwanawasa said the ... in the number of cancer patients in Zambia who have ... the state of an average 10,000 dollars per person. ...
... Madras Diabetes Research Foundation (MDRF), in collaboration with the ... Index Testing Centre in Chennai . ,For ... and its products, this is a significant development. For ... the Glycemic Index (the metabolic speed at which food ...
... of medical negligence has been registered against the premier institute ... fine of Rs five lakhs by the State Consumer Commission ... guilty of wrongly diagnosing a woman as cancer patient and ... ago. ,The Commission Bench headed by Justice J ...
Other Medicine News:Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Scottish Engineer Devises Versatile Hand 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2Health News:A Centre for Glycemic Index Testing Opened in Chennai 2Health News:AIIMS Fined Rs 5 Lakhs for Negligence 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: